Hanmi Pharmaceutical reported a 28.1% operating margin in Q2 2026, roughly double its own three-year average, on operating profit of 131.1 billion won.
Hanmi Pharmaceutical (128940) disposed of 11,180 common treasury shares to employees and officers on August 4 at KRW 345,500, the prior day's close, for a total of KRW 3.86 billion, the company said in a filing.
| Period | 128940 | KOSPI | Difference |
|---|---|---|---|
| 1 week | -7.0% | -1.5% | -5.5% |
| 1 month | +25.3% | +5.2% | +20.1% |
| 3 months | -3.7% | -22.6% | +18.9% |
| 6 months | -0.9% | +31.3% | -32.2% |
| Year to date | +4.8% | +58.7% | -53.9% |
| 1 year | +55.5% | +108.9% | -53.4% |
Closed at 55% of the way from its 52-week low (₩290,500) to its 52-week high (₩626,000).
Hanmi Pharmaceutical (KRX:128940) disposed of 11,180 common treasury shares to employees and officers on August 4 at the prior day's close of ₩345,500, for a total of ₩3.86 billion, transferred directly into recipients' brokerage accounts via Shinhan Investment. The filing's own reconciliation table flags the outcome as "inconsistent" with what the company originally scheduled: 10,402 shares planned versus 11,180 actually distributed, a gap the filing attributes to share-price movement and performance-evaluation results between the board's disposal decision and the actual settlement date. Separately, the filing notes Hanmi holds another 110,700 treasury shares acquired for a specific statutory purpose that are excluded from this table entirely.
Hanmi Pharmaceutical sells prescription drugs in Korea while developing a pipeline in obesity, metabolic disease, and rare conditions, several assets of which it has licensed to Western partners. Its long-acting drug platform, which extends how long a dose stays effective, is the basis of most of those deals. A public fight for control among the founding family has drawn attention from the English-language business press. For US investors it is a Korean company competing in the same obesity-drug field as Novo Nordisk and Eli Lilly.
| Sector | Biopharma | Employees | |
| Market | KOSPI | Founded | |
| Korean name | 한미약품 | Head office |
| Symbol | Last Price |
|---|---|
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |